Innoviva Inc (INVA): Price-to-Revenue Ratio

Corporate company logo of Innoviva Inc (INVA)

The non-cyclical nature of Innoviva, Inc. (INVA) ensures resilience during any crisis due to stable drug sales. This P/S chart confirms the strength of this trend, with the 3.00 level reflecting the current multiple. The holding's profitability is based on royalties from Trelegy, while the absence of debt and excess liquidity completely eliminate the risk of cash flow gaps.

INVA (Innoviva) P/S Multiple history from 07/04/2022 to 11/14/2026

Analytical breakdowns for Innoviva Corp (INVA)

- current quotes and average value forecast:
Market Price inva.com|INVA - Price Target Chart
- stock exchange capitalization data:
Market Value Innoviva Corp|INVA - Enterprise Value
- issuer book value statistics:
Equity per Share Innoviva|INVA - Book Capitalization|Market Capitalization to Book Value inva.com|INVA - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Innoviva, Inc.|INVA - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Innoviva Therapeutics|INVA - Company Aggregate Debts|Debts to Net Assets Innoviva Corp|INVA - Company Long-Term Debt|Company Short-Term Indebtedness Innoviva|Immediate Liquidity Ratio inva.com
- net income and valuation multiples indicators:
INVA - Company Net Income|Expected Net Profit Innoviva, Inc.|INVA - Price to Earnings Ratio|Future Price to Earnings Innoviva Inc|INVA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Innoviva Corp|INVA - Operating profit before deduction of amortization|Earnings per share for the last twelve months Innoviva|INVA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth inva.com|INVA - Net earnings per share growth this year|Expected earnings per share trend next year Innoviva, Inc.
- issuer revenue and sales details:
INVA - Revenue and Sales Volume|Company Future Sales inva.com|INVA - Price-to-Revenue Ratio|Market Cap to Projected Revenue Innoviva Corp
General company analysis:INVA, inva.com
Manufactured products of Innoviva Corp

Investors evaluate Innoviva, Inc. (INVA) through the lens of stable royalties from approved drugs, utilizing the P/S multiple to determine the value of each dollar of annual sales. This metric compares market capitalization to revenue, allowing the calculated P/S to identify deviations of the current price from the business's fundamental value. This helps determine whether the income from partnerships with pharma behemoths is overvalued or if the asset is undervalued.

Competitors of Innoviva, Inc.

IEP - Price to Sales|Price-to-Revenue Ratio Hannon Armstrong Sustainable Infrastructure HASI|Central Securities Corp - Price-to-Revenue Ratio|Cannae Corp - P/S Multiple|ECPG (Cabot Credit Details) - Market Cap to Revenue Ratio|PRAA: P/S Multiple|BGH - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Acacia Research Corporation|Market Cap to Revenue Ratio NBH (NBH Fund)|P/S Multiple GLO|Nuveen Income Fund (JRS) - Price-to-Revenue Multiple|P/S Multiple HGLB (Highland Global Allocation Fund)|Price-to-Revenue Coefficient Roma Green Finance Ltd. (ROMA)|OCCI - Price-to-Revenue Ratio|BANX (ArrowMark Financial Corp) - Market Cap to Revenue Ratio|shiplpcef.com (EDF) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio GNT|Price-to-Revenue Ratio Dominari Financial|Price to Sales hginc.com HGBL|Market Cap to Revenue RFL (Rafael Holdings)|Price-to-Revenue Ratio GRF (eaglecapitalgrowthfund.com)|P/S Multiple AAMC (Altisource Asset Management)|Price-to-Revenue Coefficient Mill City Ventures Corp (MCVT)|TTP: Market Cap to Revenue